BioLineRx (BLRX) News Today $0.55 +0.01 (+1.87%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period BioLineRx to Report Third Quarter 2024 Results on November 25, 2024November 20 at 7:19 AM | prnewswire.comBioLineRx (NASDAQ:BLRX) Coverage Initiated by Analysts at StockNews.comNovember 16, 2024 | americanbankingnews.comBioLineRx Granted Extension to Meet Nasdaq RequirementsNovember 13, 2024 | markets.businessinsider.comBioLineRx’s Motixafortide Shows Promise in Sickle Cell TrialsNovember 6, 2024 | markets.businessinsider.comBioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024November 5, 2024 | prnewswire.comBioLine RX Ltd. ADROctober 31, 2024 | wsj.comBioLineRx Announces USPTO Allowance of New Composition of Matter Patent on MotixafortideOctober 16, 2024 | finance.yahoo.comBioLine Rx (NASDAQ:BLRX) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comBioLine Rx (NASDAQ:BLRX) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comBioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell CollectionSeptember 17, 2024 | prnewswire.comBuy Rating Affirmed for Bioline RX Ltd on FDA Approval and Market Expansion PotentialSeptember 4, 2024 | markets.businessinsider.comEquities Analysts Issue Forecasts for BioLineRx Ltd.'s FY2024 Earnings (NASDAQ:BLRX)BioLineRx Ltd. (NASDAQ:BLRX - Free Report) - Equities research analysts at Zacks Small Cap increased their FY2024 earnings per share (EPS) estimates for shares of BioLineRx in a research note issued to investors on Tuesday, August 20th. Zacks Small Cap analyst J. Vandermosten now anticipates thatAugust 22, 2024 | marketbeat.comBLRX: On Track for 60% Formulary PlacementAugust 20, 2024 | finance.yahoo.comEarnings call: BioLineRx beats Q2 goals with strong APHEXDA demandAugust 19, 2024 | investing.comBioLineRx Ltd. (NASDAQ:BLRX) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | msn.comBioLineRx Ltd. (BLRX) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | seekingalpha.comBioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio UpdatesAugust 15, 2024 | prnewswire.comBioLineRx (BLRX) Scheduled to Post Earnings on ThursdayBioLineRx (NASDAQ:BLRX) will be releasing earnings before the market opens on Thursday, August 15, Zacks reports.August 9, 2024 | marketbeat.comBioLineRx to Report Second Quarter 2024 Results on August 15, 2024August 8, 2024 | prnewswire.comShort Interest in BioLineRx Ltd. (NASDAQ:BLRX) Decreases By 63.1%BioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) saw a large decrease in short interest in the month of July. As of July 15th, there was short interest totalling 119,700 shares, a decrease of 63.1% from the June 30th total of 324,300 shares. Based on an average daily volume of 347,600 shares, the days-to-cover ratio is currently 0.3 days.July 25, 2024 | marketbeat.comBioLineRx Ltd. (BLRX)July 21, 2024 | finance.yahoo.comBioLineRx Ltd. (NASDAQ:BLRX) Short Interest Up 52.9% in JuneBioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) was the recipient of a large increase in short interest in June. As of June 30th, there was short interest totalling 324,300 shares, an increase of 52.9% from the June 15th total of 212,100 shares. Based on an average daily volume of 374,900 shares, the short-interest ratio is presently 0.9 days.July 13, 2024 | marketbeat.comBioLineRx Ltd. (NASDAQ:BLRX) Short Interest UpdateBioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) was the recipient of a significant increase in short interest in May. As of May 31st, there was short interest totalling 356,200 shares, an increase of 62.6% from the May 15th total of 219,100 shares. Based on an average daily trading volume, of 427,300 shares, the short-interest ratio is currently 0.8 days.June 14, 2024 | marketbeat.comMillionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025June 5, 2024 | investorplace.comBioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)May 30, 2024 | prnewswire.comShort Interest in BioLineRx Ltd. (NASDAQ:BLRX) Decreases By 46.6%BioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) was the recipient of a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 219,100 shares, a drop of 46.6% from the April 30th total of 410,600 shares. Based on an average daily volume of 410,600 shares, the days-to-cover ratio is currently 0.5 days.May 29, 2024 | marketbeat.comBioLineRx (NASDAQ:BLRX) Releases Earnings ResultsBioLineRx (NASDAQ:BLRX - Get Free Report) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.28. The firm had revenue of $6.86 million for the quarter, compared to analyst estimates of $0.34 million. During the same period in the prior year, the business earned ($0.15) earnings per share.May 29, 2024 | marketbeat.comBioLineRx (NASDAQ:BLRX) Given "Buy" Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $21.00 price objective on shares of BioLineRx in a research note on Wednesday.May 29, 2024 | marketbeat.comBioLineRx Ltd. (NASDAQ:BLRX) Q1 2024 Earnings Call TranscriptMay 29, 2024 | msn.comBioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio UpdatesMay 28, 2024 | prnewswire.comBioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual MeetingMay 24, 2024 | prnewswire.comBioLineRx to Report First Quarter 2024 Results on May 28, 2024May 22, 2024 | finance.yahoo.comBioLineRx to Report First Quarter 2024 Results on May 28, 2024May 22, 2024 | prnewswire.comBioLineRx Announces Receipt of Nasdaq Minimum Bid Price NotificationMay 17, 2024 | prnewswire.comShort Interest in BioLineRx Ltd. (NASDAQ:BLRX) Drops By 47.6%BioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) was the target of a significant decline in short interest in April. As of April 30th, there was short interest totalling 410,600 shares, a decline of 47.6% from the April 15th total of 783,600 shares. Based on an average daily volume of 416,500 shares, the days-to-cover ratio is currently 1.0 days.May 11, 2024 | marketbeat.comBioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024May 6, 2024 | prnewswire.comBuy Rating on Bioline RX Ltd for Breakthrough Stem Cell Mobilization and Enhanced Apheresis EfficiencyApril 18, 2024 | markets.businessinsider.comBioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual MeetingApril 17, 2024 | finance.yahoo.comBioLineRx (NASDAQ:BLRX) Rating Increased to Sell at StockNews.comStockNews.com upgraded shares of BioLineRx to a "sell" rating in a research report on Friday.April 12, 2024 | marketbeat.comBioLineRx secures $20 million in BlackRock financingApril 11, 2024 | investing.comBioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing AgreementApril 10, 2024 | finance.yahoo.comBioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing AgreementApril 10, 2024 | prnewswire.comBioLineRx Announces $6 Million Registered Direct OfferingApril 1, 2024 | prnewswire.comFY2024 Earnings Forecast for BioLineRx Ltd. (NASDAQ:BLRX) Issued By HC WainwrightBioLineRx Ltd. (NASDAQ:BLRX - Free Report) - Investment analysts at HC Wainwright cut their FY2024 earnings estimates for BioLineRx in a report issued on Tuesday, March 26th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings of ($1.03) per share forMarch 29, 2024 | marketbeat.comShort Interest in BioLineRx Ltd. (NASDAQ:BLRX) Expands By 76.6%BioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 324,700 shares, an increase of 76.6% from the February 29th total of 183,900 shares. Based on an average daily trading volume, of 316,300 shares, the days-to-cover ratio is presently 1.0 days.March 28, 2024 | marketbeat.comBioLineRx Ltd.: BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio UpdatesMarch 28, 2024 | finanznachrichten.deResearch Analysts Issue Forecasts for BioLineRx Ltd.'s Q1 2024 Earnings (NASDAQ:BLRX)BioLineRx Ltd. (NASDAQ:BLRX - Free Report) - Analysts at HC Wainwright issued their Q1 2024 earnings estimates for shares of BioLineRx in a research note issued to investors on Tuesday, March 26th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will earn ($0.29) per sMarch 28, 2024 | marketbeat.comBioLineRx (NASDAQ:BLRX) Upgraded to Sell at StockNews.comStockNews.com upgraded shares of BioLineRx to a "sell" rating in a report on Wednesday.March 27, 2024 | marketbeat.comBioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | finance.yahoo.comBLRX: First Aphexda Sales RecognizedMarch 27, 2024 | finance.yahoo.com Get BioLineRx News Delivered to You Automatically Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development… YES, I WANT THE #1 CRYPTO NOW BLRX Media Mentions By Week BLRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BLRX News Sentiment▼0.170.45▲Average Medical News Sentiment BLRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BLRX Articles This Week▼21▲BLRX Articles Average Week Get BioLineRx News Delivered to You Automatically Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GALT News Today DMAC News Today MDWD News Today ADAP News Today ACTU News Today SCPH News Today LFVN News Today FULC News Today OGI News Today TSVT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BLRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioLineRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
